Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.[2]
Oxotremorine also produces antipsychotic effects.[3]
References
^Tang C, Castoldi AF, Costa LG (April 1993). "Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes". Biochemistry and Molecular Biology International. 29 (6): 1047–54.
PMID8330013.
INIST4025194.
^Craig CR, Stitzel RE, eds. (2004). Modern Pharmacology with Clinical Applications. Lippincott Williams & Wilkins.
ISBN978-0-7817-3762-3.[page needed]
^Maehara S, Hikichi H, Satow A, Okuda S, Ohta H (November 2008). "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia". Pharmacology, Biochemistry, and Behavior. 91 (1): 140–9.
doi:
10.1016/j.pbb.2008.06.023.
PMID18651995.
S2CID12225821.
INIST20678587.
Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.[2]
Oxotremorine also produces antipsychotic effects.[3]
References
^Tang C, Castoldi AF, Costa LG (April 1993). "Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes". Biochemistry and Molecular Biology International. 29 (6): 1047–54.
PMID8330013.
INIST4025194.
^Craig CR, Stitzel RE, eds. (2004). Modern Pharmacology with Clinical Applications. Lippincott Williams & Wilkins.
ISBN978-0-7817-3762-3.[page needed]
^Maehara S, Hikichi H, Satow A, Okuda S, Ohta H (November 2008). "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia". Pharmacology, Biochemistry, and Behavior. 91 (1): 140–9.
doi:
10.1016/j.pbb.2008.06.023.
PMID18651995.
S2CID12225821.
INIST20678587.